In child-crippling mucolipidosis IV, drug shows hope in lab cultures

May 29, 2018, Georgia Institute of Technology
Paul suffers from mucolipidosis IV, a rare hereditary disease. Used with the express permission of Paul's mother. For use only for reporting on the research collaboration between Georgia Tech and Mass General to fight MLIV. Credit: ML4.org

Mucolipidosis IV debilitates afflicted children's nervous systems in their first year of life, steals their eyesight in their teens and takes their lives in their twenties, and so far, there is no therapy to fight it. Now, lab tests using an existing prescription drug have shown initial hope for a future treatment.

Fingolimod is used to treat a form of multiple sclerosis and is already FDA-approved. Researchers at the Georgia Institute of Technology, and at the Massachusetts General Hospital Research Institute have led successful testing of fingolimod, in vitro, i.e. on , in cells originating from the brains of mice genetically augmented to mimic mucolipidosis IV (MLIV).

The next step will be tests in living mice, and researchers are hopeful that continued research progress may lead to a quicker than usual approval for human clinical drug trials. Fingolimod has not been tested on human MLIV cells and is not yet prescribed to treat MLIV.

The researchers published their study in the latest edition of the journal Human Molecular Genetics. Their work was funded by the ML4 Foundation.

Cellular junk accumulation

Mucolipidosis IV is a rare hereditary disease with a cruelty that can rival cerebral palsy's. MLIV strikes very early in life and goes from bad to worse.

"Around the age of 9 months, you see cognitive deficits," said Levi Wood, an assistant professor in Georgia Tech's School of Mechanical Engineering. Wood's research focuses on neurological diseases. "The children never learn to speak, and hardly at all to walk."

"When they go blind, it changes everything so badly, because the children stop recognizing faces, including their parents'," said Yulia Grishchuk, a junior faculty member at Mass General and Harvard Medical School. She co-led the study with Wood.

MLIV is caused by a single mutated gene.

"It disrupts the lysosome (a cell organelle), which is responsible for recycling waste, and this causes it to pile up in the cell," Grishchuk said. "Junk accumulates in all the cells of the body, but the brain suffers the most, and the eyes."

Lab success: Astrocyte observation

The disease particularly throws off a group of cells in the brain called glial cells. One type, oligodendrocytes, produces the white sheathing called myelin that protects many neurons.

"These patients, and also our lab mice, have ineffective myelination," Wood said. "That's one thing that may be impeding ."

Other glial cells, microglia and astrocytes, both have immune functions in the brain, and in this study, the researchers were able to observe for the first time that the latter were not behaving normally.

"The astrocytes' activity is unusual in this disease and associated with increased inflammation," Grishchuk said.

Daniella suffers from mucolipidosis IV, a hereditary disease for which there is no treatment. Georgia Tech and Mass General / Havard Medical School are working to change that. Only for use in reporting on this specific collaboration to fight MLIV. Credit: ML4 Foundation with the express permission of Daniella's parents

Grishchuk trained in the lab of Susan Slaugenhaupt, an MLIV pioneer who initially discovered the causal gene at Mass General and developed the mouse model used to study and fight the disease. Slaugenhaupt collaborated on this study.

Lab success: Astrocyte regulation

A certain type of , remitting-relapsing MS (RRMS), shares this odd astrocyte behavior, which gave the researchers the idea of testing a drug used to treat that disease in MLIV cell samples.

"We thought fingolimod would have a good chance because it works on astrocytes in MS," Wood said.

It tested successfully in the researchers' mouse-MLIV-astrocyte lab cultures, inhibiting the astrocytes' abnormal behavior. Now, the researchers want to move on to live mouse models to see if treatment helps brain function.

Fingolimod was recently improved for pediatric treatment of RRMS. Also, if it positively affects astrocytes in , there is hope fingolimod could also improve other ' functioning.

MLIV's particular challenges

Very few people carry the mutated gene that causes MLIV, and the gene is recessive, meaning that to get the disease, not only do both parents have to carry it, but both have to pass on their respective recessive gene to the child.

Since the affliction is so rare, parents of a child with MLIV usually spend years going through misdiagnoses before correctly determining their child's disease. And, ironically, though the effects of the disease are obviously visible, early on, neural damage is not.

"It's neurodevelopmental in very early childhood. The neurodegeneration kicks in much later in life," Grishchuk said.

Once a clinician or parent stumbles onto the disorder in medical literature, it can be confirmed by a genetic test. But then the parents are confronted with the cruel fact that there is no treatment at all for MLIV.

Research fight against MLIV

As with many rare diseases, research and development funding for MLIV is scarce, so researchers are pushed to find promise in existing FDA-approved medications for other conditions, so that clinical trials may become more likely.

If fingolimod does make it to a clinical trial to treat MLIV, it may be a one-shot proposition. If the trial fails, then subsequent clinical trials may not be possible for many years, since the patient pool is very small and participation in a failed clinical trial often rules out a patient's inclusion in further trials with different medications.

If the drug advances to become an available treatment, it would ideally be combined with early detection, so that therapy could begin as young as possible, thus preempting neurological ravages and rescuing brain function without delay.

Explore further: Researchers discover a possible first therapy for an uncommon childhood disease

More information: Laura Weinstock et al, Fingolimod Phosphate Inhibits Astrocyte Inflammatory Activity in Mucolipidosis IV, Human Molecular Genetics (2018). DOI: 10.1093/hmg/ddy182

Related Stories

Researchers discover a possible first therapy for an uncommon childhood disease

June 28, 2016
Mucolipidosis IV (MLIV) is a devastating early childhood neurological disease characterized by progressive neurodegeneration, leading to severe impairments in muscle coordination, cognitive deficits and retinal degeneration ...

Receptor variation influences fingolimod efficacy in mouse multiple sclerosis models

June 16, 2016
Multiple sclerosis (MS) is an autoimmune disorder that results in demyelination of neurons. The FDA-approved drug fingolimod (Gilenya, FTY-720) modulates signaling by the bioactive lipid sphingosine-1-phosphate (S1P), which ...

Brain astrocytes linked to Alzheimer's disease

November 20, 2017
Astrocytes, the supporting cells of the brain, could play a significant role in the pathogenesis of Alzheimer's disease (AD), according to a new study from the University of Eastern Finland. This is the first time researchers ...

Researchers discovered new applications of the drug fingolimod to improve cognitive deficits in Huntington's disease

July 14, 2015
Fingolimod, a drug used to treat multiple sclerosis, restores hippocampal synaptic plasticity and improves memory function. This is the main conclusion of a study developed by researchers at the University of Barcelona (UB) ...

Astrocyte findings suggest new options against Alzheimer's

May 4, 2018
A study by scientists of the German Center for Neurodegenerative Diseases (DZNE) points to a potential approach against Alzheimer's disease. In studies with mice, the researchers were able to show that blocking a particular ...

Scientists use gene expression to understand how astrocytes change with age

January 11, 2018
Potentially explaining why even healthy brains don't function well with age, Salk researchers have discovered that genes that are switched on early in brain development to sever connections between neurons as the brain fine-tunes, ...

Recommended for you

Study reveals broad 'genetic architectures' of traits and diseases

August 13, 2018
Scientists at Johns Hopkins Bloomberg School of Public Health have developed a powerful method for characterizing the broad patterns of genetic contributions to traits and diseases. The new method provides a "big picture" ...

Researchers predict risk for common deadly diseases from millions of genetic variants

August 13, 2018
A research team at the Broad Institute of MIT and Harvard, Massachusetts General Hospital (MGH), and Harvard Medical School reports a new kind of genome analysis that could identify large fractions of the population who have ...

Genetic tools uncover cause of childhood seizure disorder missed by other methods

August 13, 2018
Early childhood seizures result from a rare disease that begin in the first months of life. Researchers at University of Utah Health have developed high-tech tools to uncover the genetic cause of the most difficult to diagnose ...

Evolutionary changes in the human brain may have led to bipolar disorder and schizophrenia

August 9, 2018
The same aspects of relatively recent evolutionary changes that make us prone to bad backs and impacted third molars may have generated long, noncoding stretches of DNA that predispose individuals to schizophrenia, bipolar ...

Genetic mutation underlying severe childhood brain disorder identified

August 9, 2018
Ashleigh Schaffer, Ph.D., assistant professor of genetics at Case Western Reserve University School of Medicine, and a team of global genetics experts have discovered a genetic mutation and the faulty development process ...

Unexpected outcomes sound warning for treatment of genetic diseases using gene editing in embryos

August 9, 2018
New research led by the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide has uncovered a significant hurdle for realising the potential benefits of gene editing in embryos.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.